Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
  • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles

Definitions

• the present invention relates to a novel process for preparing dihydroisoxazole derivatives.
• Dihydroisoxazoles are valuable precursors of fungicidal or herbicidal active ingredients (US 2011/0223257 Al, WO 1995/007897 Al) or drugs like anti-cancer HDAC-inhibitors (WO 2008/006561 Al).
• Known dihydroisoxazole derivatives are prepared by the treatment of an unsaturated ketone with hydroxamic acid derivative and subsequent ring closure (Scheme 1). Examples can be found in A.A.R. Mohamed and M.H.A. Eman, Monatsh. Chem., 140, 229 (2009), T. Shah and V. Desai, J. Serb. Chem. Soc., 72, 443 (2007), S.B. Lohiya and B J.
• dihydroisoxazole derivatives can be prepared by 1,3-dipole addition (Tetrahedron 2000, 56, 1057 - 1064; Chemical & Pharmaceutical Bulletin 1976, 24, 1757 or WO2011/085170) (Scheme 2):
• R 1 is ketone
• R 2 is phenyl which is optionally substituted once or more often independently of one another by halogen and C 1-C4- alkylsulfonyloxy;
• R 3 is selected from chlorine or bromine; characterized in that hydroxyiminochlorides of the formula (II),
• R 3 is as defined above are reacted via an elimination reaction to compounds of formula (III)
• R 2 is phenyl substituted with chlorine and methylsulfonyloxy; R 3 is chlorine.
• Optionally substituted groups may be mono- or polysubstituted, where the substituents in the case of polysubstitutions may be the same or different.
• collective terms were used which are generally representative of the following substituents:
• Halogen fluorine, chlorine, bromine and iodine and preferably fluorine, chlorine, bromine and more preferably chlorine.
• Alkyl saturated, straight-chain or branched hydrocarbyl radicals having 1 to 4 carbon atoms, for example (but not limited to) Ci-C4-alkyl such as methyl, ethyl, propyl, 1 -methylethyl, butyl, 1 -methylpropyl, 2- methylpropyl, 1,1 -dimethylethyl.
• Ci-C4-alkyl such as methyl, ethyl, propyl, 1 -methylethyl, butyl, 1 -methylpropyl, 2- methylpropyl, 1,1 -dimethylethyl.
• This definition also applies to alkyl as part of a composite substituent, for example alkylsulphonyl, alkoxy.
• inventive compounds may be present as mixtures of any different isomeric forms possible, especially of stereoisomers, for example E and Z isomers, threo and erythro isomers, and optical isomers, but if appropriate also of tautomers.
• stereoisomers for example E and Z isomers, threo and erythro isomers, and optical isomers, but if appropriate also of tautomers.
• E and the Z isomers are disclosed and claimed, as are the threo and erythro isomers, and also the optical isomers, any mixtures of these isomers, and also the possible tautomeric forms.
• Hydroxyiminochlorides of the formula (II) are reacted via an elimination reaction to compounds of formula (III) which are in situ transformed to compounds of formula (I) after the addition of (IV) in the presence of a base, an acid and a solvent in acidic pH.
• the reaction is conducted under acidic conditions by addition of a buffer system or by addition of a weak base to capture spontaneously eliminated HC1 thereby ensuring that no further deprotonation of compounds of formula (IV), (III) or (I) occurs.
• the pH level is between pH 3 and pH 5, more preferably it is between pH 3.5 and pH 4.5.
• the weak base can be for example taken from the group of hydrogen carbonates, like sodium hydrogencarbonate or potassium hydrogencarbonate, or from the group of hydrogenphosphates, like (di)sodium (di)hydrogenphosphate or( di)potassium (di)hydrogenphosphate or from the group of alkali salts of organic acids, like sodium acetate or sodium benzoate.
• Preferred is sodium hydrogencarbonate.
• the buffer system consists of a weak acid and a salt of the weak acid, it can be for example taken from acetic acid / sodium acetate or acetic acid / ammonium acetate or formic acid / sodium formiate or dihydrogenphosphate / monohydrogenphosphate. Preferred is acetic acid / sodium acetate.
• the reaction can be performed in a solvent, taken from the group of halogenalkanes like methylene chloride or 1 ,2-dichloroethane or from the group of aromatic compounds like benzene, toluene, xylene, chlorobenzene, dichlorobenzene or from the group of polar aprotic solvents like N,N-dialkylformamide, - acetamide, N-methylpyrrolidon, dimethylpropylene urea, tetramethyl urea or in nitriles like acetonitriles, propionitrile or butyronitrile, in alkohols like methanol, ethanol, n-propanol, iso-propanol, n-butanol or iso- butanol, in ethers like diethylether, tert.butylmethylether, diisopropylether, in ketones like acetone, methylisobutyl ketone in carb
• the reaction can be performed in mixtures of these solvents.
• the reaction can be performed in acetonitrile, ethyl acetate or in a mixture thereof.
• the can reaction be performed in the presence of water.
• the reaction can be performed in a temperature range from -10°C to the boiling point of the solvent, which is used, preferable in the range from 0°C to 50°C, more preferable in the range from 5°C to 40°C.
• a mixture of 92g (0.55mol) ethyl-4-chloro acetoacetate and 542g 37%> hydrochloric acid is stirred at 25°C for 24 hours.
• the mixture is concentrated to 320g at 40°C under vacuum and cooled to 5°C. 215g of 20% sodium hydroxide is added, so that the internal temperature did not exceed 10°C.
• the mixture is cooled to 0°C and 159g of a 20% solution of sodium nitrite is added during 15 minutes. Gas evolution is observed and finally )-l-chloro-3-(hydroxyimino)acetone precipitates.
• the mixture After 30minutes stirring at 0°C, the mixture is extracted once with 360ml ethyl acetate and twice with 120ml ethyl acetate each. To the combined organic phases is added 51g sodium hydrogencarbonate and 29g water. 37.6g of chlorine gas is introduced during 30min at a temperature of 0-5°C. After stirring for 30min at 0-5°C half of the mixture is separated and to this is added 46,4g of 3-chloro-2-vinylphenyl methanesulfonate (0.199mol). the mixture is warmed to 35°C and stirred, while the pH of the mixture is adjusted between 4.3 to 4.5 by addition of a 25% aqueous solution of potassium hydrogencarbonate.
• the second half of the chloro oxime solution is added after 1 hour. Stirring at 35°C is continued for further 4 hours, while the pH is kept between 4.3 and 4.5 with a total amount of 129g 25% potassium hydrogencarbonate.
• the mixture is cooled to 20°C and the phases are separated. The organic phase is concentrated to 106g at 30°C under vacuum. 160ml of ethanol is added to the residual oil and the mixture is heated to 70°C. then the mixture is slowly cooled to 20°C with intermediate seeding. The product precipiates and stirring is continued at 0°C for 1 hour. The product is filtered off, washed with cold ethanol and dried at 30°C in vacuum.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Wood Science & Technology (AREA)
• Plant Pathology (AREA)
• Engineering & Computer Science (AREA)
• Dentistry (AREA)
• Pest Control & Pesticides (AREA)
• Agronomy & Crop Science (AREA)
• Zoology (AREA)
• Environmental Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=50828731

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (2)

Citations (3)

Family Cites Families (7)

• 2015
  • 2015-05-26 TW TW104116745A patent/TWI665192B/zh active
  • 2015-05-27 ES ES15724677T patent/ES2730048T3/es active Active
  • 2015-05-27 JP JP2016569396A patent/JP6533798B2/ja active Active
  • 2015-05-27 WO PCT/EP2015/061623 patent/WO2015181189A1/en not_active Ceased
  • 2015-05-27 MX MX2016015623A patent/MX382631B/es unknown
  • 2015-05-27 KR KR1020167035419A patent/KR102337028B1/ko active Active
  • 2015-05-27 BR BR112016027824-0A patent/BR112016027824B1/pt active IP Right Grant
  • 2015-05-27 EP EP15724677.8A patent/EP3148976B1/en active Active
  • 2015-05-27 CN CN201580027637.2A patent/CN106414417B/zh active Active
  • 2015-05-27 US US15/314,446 patent/US9796690B2/en active Active
  • 2015-05-27 DK DK15724677.8T patent/DK3148976T3/da active
• 2016
  • 2016-10-27 IL IL248568A patent/IL248568B/en active IP Right Grant

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events